摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

苄氧羰基-亮氨酰胺 | 4801-79-0

中文名称
苄氧羰基-亮氨酰胺
中文别名
CBZ-亮氨酸酰胺
英文名称
N-benzyloxycarbonyl-L-leucinamide
英文别名
Z-Leu-NH2;Cbz-L-Leu-NH2;Benzyloxycarbonyl-L-leucin-amid;N-[(Phenylmethoxy)carbonyl]-L-leucinamide;(S)-Benzyl (1-amino-4-methyl-1-oxopentan-2-yl)carbamate;benzyl N-[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]carbamate
苄氧羰基-亮氨酰胺化学式
CAS
4801-79-0
化学式
C14H20N2O3
mdl
——
分子量
264.324
InChiKey
JZEYMGMOBIYUOV-LBPRGKRZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    124-125 °C(Solv: water (7732-18-5); ethanol (64-17-5))
  • 沸点:
    461.5±38.0 °C(Predicted)
  • 密度:
    1.124±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    19
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    81.4
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2924299090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件:2-8°C,干燥密封。

SDS

SDS:51cdd347679dd1bb68abb284762ed89f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Z-Leu-nh2
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Z-Leu-nh2
CAS number: 4801-79-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H20N2O3
Molecular weight: 264.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    苄氧羰基-亮氨酰胺 在 palladium on activated charcoal 氢气 作用下, 以 四氢呋喃甲醇二氯甲烷 为溶剂, -70.0~25.0 ℃ 、101.33 kPa 条件下, 反应 95.0h, 生成 (3R,6S)-6-isobutyl-3-methyl-3-trifluoromethylpiperazine-2,5-dione
    参考文献:
    名称:
    Asymmetric synthesis of α-trifluoromethyl substituted aminoacids via 3-hydroxy-3-trifluoromethyl-2,5-diketopiperazines
    摘要:
    The diastereoselective reaction of organometallic compounds (RMgX, R(2)Cd) with in situ generated trifluoromethyl substituted cyclic acyl imines representing homochiral alpha-electrophilic 3,3,3-trifluoroalanine equivalents gives 3-alkyl-3-trifluoromethyl-2,5-diketopiperazines. The corresponding homochiral dipeptide esters are obtained on acidolysis in methanol.
    DOI:
    10.1016/0957-4166(94)80055-3
  • 作为产物:
    参考文献:
    名称:
    水性和非水性环境中末端取代的氨基酸之间的相互作用。25°C 下水和 N,N-二甲基甲酰胺中的焓相互作用系数
    摘要:
    甘氨酸、L-丙氨酸、L-缬氨酸、L-亮氨酸和 L-苯丙氨酸的 N-乙酰酰胺溶解在作为溶剂的 N,N-二甲基甲酰胺 (DMF) 中的稀释焓已在 25°C 下测量。已对获得的结果进行分析,以给出溶质的焓相互作用(或维里)系数,并将这些系数与先前在水性系统中获得的信息进行比较。两种溶剂的相互作用性质存在显着差异,虽然 Savage 和 Wood 的加法方法适用于水中的溶质,但不适合表示 DMF 中的相互作用。在 DMF 中的焓第二维里系数与侧链在球状蛋白质中接近的倾向之间存在相关性。
    DOI:
    10.1007/bf00648899
点击查看最新优质反应信息

文献信息

  • Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates
    作者:Santiago Royo、Tanja Schirmeister、Marcel Kaiser、Sascha Jung、Santiago Rodríguez、José Manuel Bautista、Florenci V. González
    DOI:10.1016/j.bmc.2018.07.015
    日期:2018.9
    the parasitic cysteine proteases rhodesain, cruzain and falcipain-2 related to sleeping sickness, Chagas disease and malaria, respectively. They have also been tested against human cathepsins B and L1 for selectivity. Dipeptidyl enoates resulted to be irreversible inhibitors of these enzymes. Some of the members of the family are very potent inhibitors of parasitic cysteine proteases displaying k2nd
    已经制备了二肽烯醇酯家族,并针对与睡眠病,恰加斯病和疟疾有关的寄生性半胱氨酸蛋白酶罗氏蛋白酶,克鲁萨因和falcipain-2进行了测试。还针对人组织蛋白酶B和L1对它们进行了选择性测试。二肽烯醇酸酯是这些酶的不可逆抑制剂。该家族中的某些成员是非常有效的寄生半胱氨酸蛋白酶抑制剂,显示出7个数量级的k 2nd(M -1 s -1)值。还进行了体内抗原生动物测试。抑制剂对恶性疟原虫,布鲁氏锥虫,克鲁氏锥虫的微摩尔范围显示IC 50值甚至对利什曼原虫(Leishmania donovanii)的价值更低。
  • Protease inhibitors
    申请人:——
    公开号:US20020049316A1
    公开(公告)日:2002-04-25
    The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.
    本发明提供了一种公式(I)的化合物,其抑制蛋白酶,包括卡特普辛K,以及这些化合物的药物组合物,以及治疗骨量过度流失或软骨或基质降解疾病的方法,包括骨质疏松症;牙龈疾病,包括牙龈炎和牙周炎;关节炎,更具体地说是骨关节炎和类风湿关节炎;帕吉特病;高钙血症或恶性肿瘤;以及代谢性骨病。
  • Synthesis of Terminal Thiazoles from <i>N</i>-Protected Amino Acids and a Study of Their Antibacterial Activities
    作者:H. S. Lalithamba、K. Uma、T. S. Gowthami、G. Nagendra
    DOI:10.1080/00304948.2020.1721959
    日期:2020.5.3
    located thiazole derivatives. Several methods for the synthesis of thiazoles have been reported as follows: (i) thiazolecontaining amino acids were synthesized by condensation-cyclization, (ii) Ling and his group prepared 1,2,4-triazole-linked thiazole derivatives from the reaction of a-bromo substituted acetophenones and thiourea, (iii) Wardakhan and his co-workers synthesized several thiazole derivatives
    噻唑在有机化学领域具有特殊意义。氨基酸衍生的噻唑在生物活性物质(如硫肽抗生素)中包含一个共同的基序。因此,噻唑的制备和反应对于药物和精细化学品的合成具有重要意义。报道了从磺酰叠氮化物、末端炔烃和硫羰酯通过消除磺酰基制备 2,5-二取代噻唑的顺序程序。氨基硫脲衍生物产生噻唑的环化反应也已被探索。特别是,我们可以注意到 4-取代苯腈和 L-半胱氨酸的环化反应生成了噻唑酯,然后用选定的醇酯化和由 BrCCl3/DBU 介导的噻唑啉酯的氧化。在室温下通过金催化氧化有效地制备了噻唑及其衍生物。此外,11-溴-10-氧代十一烷酸与乙酰胺和硫脲反应生成位于末端的噻唑衍生物。已经报道了几种合成噻唑的方法如下:(i)通过缩合环化合成含噻唑的氨基酸,(ii)Ling 和他的团队从 a 的反应制备了 1,2,4-三唑连接的噻唑衍生物。 -溴取代的苯乙酮和硫脲,(iii) Wardakhan 和他的同事从哒嗪-3-肼酸合成了几种噻唑衍生物,以及
  • 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US05223516A1
    公开(公告)日:1993-06-29
    Compounds of the formula ##STR1## wherein Y can be tetrazolyl are disclosed. These compounds are useful as cardiovascular agents.
    公开了式子##STR1##中Y可以是四唑基的化合物。这些化合物可用作心血管药物。
  • [EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER PAR DES AMIDES D'ACIDE ARYL ALCANOIQUE
    申请人:ELAN PHARM INC
    公开号:WO2003103653A1
    公开(公告)日:2003-12-18
    Disclosed are methods for treating Alzheimer’s disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula 1 (1) wherein the variables R1-R8 and X are defined herein.
    揭示了一种治疗阿尔茨海默病和其他疾病,和/或抑制β-分泌酶,和/或通过使用式1(1)中定义的化合物在哺乳动物体内抑制Aβ肽的沉积的方法。其中变量R1-R8和X在此处定义。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物